[Atrium-related hepatitis. Report of four cases].
Four patients developed acute hepatitis after receiving Atrium, an association of phenobarbital, febarbamate and difebarbomate, for the treatment of tremor or for the prevention of alcohol withdrawal symptoms. Hepatitis occurred 1 to 3 months after treatment. Asthenia was the unique clinical manifestation. Marked increase in serum aminotransferases and gamma-glutamyltranspeptidase levels were the main biological features. Histological examination showed liver cell necrosis in two cases, prominent in the centrolobular area in one case. There was no case of hepatic failure. Atrium withdrawal was followed by complete recovery within 6 to 12 weeks. The mechanism of Atrium hepatotoxicity remains unknown.
Unité de Recherches de Physiopathologie Hépatique (INSERM U24) et Service d'Hépatologie, Clichy.
Y
Y
Horsmans
D
D
Larrey
D
D
Pessayre
B
B
Rueff
C
C
Degott
J P
JP
Benhamou
D000368:Aged; D000369:Aged, 80 and over; D000410:Alanine Transaminase / Q000097:blood; D000430:Alcohol Withdrawal Delirium / Q000188:drug therapy / Q000517:prevention & control; D001219:Aspartate Aminotransferases / Q000097:blood; D001463:Barbiturates / Q000009:adverse effects* / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010634:Phenobarbital / Q000009:adverse effects* / Q000627:therapeutic use; D011619:Psychotropic Drugs / Q000009:adverse effects / Q000627:therapeutic use; D005723:gamma-Glutamyltransferase / Q000097:blood
D001463:Barbiturates; D004338:Drug Combinations; D011619:Psychotropic Drugs; C006648:difebarbamate, febarbamate, phenobarbital drug combination; D005723:gamma-Glutamyltransferase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D010634:Phenobarbital
Hépatites au cours de l'administration d'Atrium. Observation de quatre cas.